Ülke: Kanada
Dil: İngilizce
Kaynak: Health Canada
VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE)
WYETH CANADA
N06AX16
VENLAFAXINE
75MG
TABLET
VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) 75MG
ORAL
100
Prescription
SELECTIVE SEROTONIN AND NOREPINEPHRINE-REUPTAKE INHIBITORS
Active ingredient group (AIG) number: 0131294001; AHFS:
CANCELLED POST MARKET
2004-08-19
PRODUCT MONOGRAPH Pr EFFEXOR ® (Venlafaxine Hydrochloride) Tablets Pr EFFEXOR ® XR (Venlafaxine Hydrochloride) Extended Release Capsules ANTIDEPRESSANT/ANXIOLYTIC WYETH CANADA DATE OF PREPARATION: MONTREAL, CANADA July 18, 1994 Control Number: DATE OF REVISION: 094122 November 16, 2004 THIS PRODUCT MONOGRAPH IS THE EXCLUSIVE PROPERTY OF WYETH CANADA AND CANNOT BE REFERENCED, PUBLISHED OR COPIED WITHOUT THE WRITTEN APPROVAL OF WYETH CANADA. ©Wyeth Canada 2 EFFEXOR/EFFEXOR XR (Venlafaxine HCl) PRODUCT MONOGRAPH TABLE OF CONTENTS PAGE ACTIONS AND CLINICAL PHARMACOLOGY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 INDICATIONS AND CLINICAL USE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 CONTRAINDICATIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 WARNINGS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 PRECAUTIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 General . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 Discontinuation Symptoms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28 Use in Pregnancy, Labour and Delivery, and in Nursing Mothers . . . . . . . . . . . . . . . . . 36 Paediatric Use . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38 Use in the Elderly . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38 Drug Interactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38 Drug Abuse and Dependence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47 ADVERSE Belgenin tamamını okuyun